

# Catharine H Clark

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8276398/publications.pdf>

Version: 2024-02-01

88  
papers

5,097  
citations

159525

30  
h-index

88593

70  
g-index

88  
all docs

88  
docs citations

88  
times ranked

5371  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a heterogeneous phantom to measure range in clinical proton therapy beams. <i>Physica Medica</i> , 2022, 93, 59-68.	0.4	3
2	The 3rd ESTRO-EFOMP core curriculum for medical physics experts in radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 170, 89-94.	0.3	11
3	SEAFARER â€œ A new concept for validating radiotherapy patient specific QA for clinical trials and clinical practice. <i>Radiotherapy and Oncology</i> , 2022, 171, 121-128.	0.3	6
4	Volumetric modulated arc therapy (VMAT): a review of clinical outcomesâ€”what is the clinical evidence for the most effective implementation?. <i>British Journal of Radiology</i> , 2022, 95, .	1.0	17
5	An end-to-end assessment on the accuracy of adaptive radiotherapy in an MR-linac. <i>Physics in Medicine and Biology</i> , 2021, 66, 055021.	1.6	11
6	In reply to the letter to the editor: â€œIn reply to Fiorino et al: The central role of the radiation oncologist in the multidisciplinary and multiprofessional model of modern radiation therapyâ€” <i>Radiotherapy and Oncology</i> , 2021, 155, e22-e23.	0.3	0
7	Towards an updated ESTRO-EFOMP core curriculum for education and training of medical physics experts in radiotherapy â€œ A survey of current education and training practice in Europe. <i>Physica Medica</i> , 2021, 84, 65-71.	0.4	8
8	Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency. <i>Radiotherapy and Oncology</i> , 2021, 159, 106-111.	0.3	21
9	Clinical use, challenges, and barriers to implementation of deformable image registration in radiotherapy â€œ the need for guidance and QA tools. <i>British Journal of Radiology</i> , 2021, 94, 20210001.	1.0	7
10	Quantification of the uncertainties within the radiotherapy dosimetry chain and their impact on tumour control. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 19, 33-38.	1.2	2
11	Professional practice changes in radiotherapy physics during the COVID-19 pandemic. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 19, 25-32.	1.2	5
12	Quality assurance of dysphagia-optimised intensity modulated radiotherapy treatment planning for head and neck cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 20, 46-50.	1.2	2
13	IAEA methodology for on-site end-to-end IMRT/VMAT audits: an international pilot study. <i>Acta OncolÃ³gica</i> , 2020, 59, 141-148.	0.8	9
14	Grand challenges for medical physics in radiation oncology. <i>Radiotherapy and Oncology</i> , 2020, 153, 7-14.	0.3	33
15	Multivariate log file analysis for multi-leaf collimator failure prediction in radiotherapy delivery. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 15, 72-76.	1.2	8
16	Automatic evaluation of contours in radiotherapy planning utilising conformity indices and machine learning. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 16, 149-155.	1.2	7
17	Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines. <i>Radiotherapy and Oncology</i> , 2020, 150, 30-39.	0.3	53
18	Comparing Proton to Photon Radiotherapy Plans: UK Consensus Guidance for Reporting Under Uncertainty for Clinical Trials. <i>Clinical Oncology</i> , 2020, 32, 459-466.	0.6	16

#	ARTICLE	IF	CITATIONS
19	Multi-institutional dosimetric delivery assessment of intracranial stereotactic radiosurgery on different treatment platforms. <i>Radiotherapy and Oncology</i> , 2020, 147, 153-161.	0.3	10
20	Tissue mimicking materials for imaging and therapy phantoms: a review. <i>Physics in Medicine and Biology</i> , 2020, 65, .	1.6	74
21	Adapting training for medical physicists to match future trends in radiation oncology. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 11, 71-75.	1.2	6
22	Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer. <i>Clinical Oncology</i> , 2019, 31, 611-620.	0.6	12
23	Thermoluminescence measurements of eye-lens dose in a multi-centre stereotactic radiosurgery audit. <i>Radiation Physics and Chemistry</i> , 2019, 155, 75-81.	1.4	5
24	Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 51-60.	6.3	697
25	Novel methodologies for dosimetry audits: Adapting to advanced radiotherapy techniques. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 5, 76-84.	1.2	18
26	The role of dosimetry audit in achieving high quality radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 5, 85-87.	1.2	21
27	Remote beam output audits: A global assessment of results out of tolerance. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 7, 39-44.	1.2	19
28	OC-0611: Modelling the clinical impact of machine specific dose variations on outcome using national data. <i>Radiotherapy and Oncology</i> , 2018, 127, S322.	0.3	0
29	A national dosimetry audit for stereotactic ablative radiotherapy in lung. <i>Radiotherapy and Oncology</i> , 2017, 122, 406-410.	0.3	31
30	Characterisation of a plastic scintillation detector to be used in a multicentre stereotactic radiosurgery dosimetry audit. <i>Radiation Physics and Chemistry</i> , 2017, 140, 373-378.	1.4	19
31	National audit of a system for rectal contact brachytherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2017, 1, 1-5.	1.2	7
32	The role of dosimetry audit in lung SBRT multi-centre clinical trials. <i>Physica Medica</i> , 2017, 44, 171-176.	0.4	32
33	Adaptation and validation of a commercial head phantom for cranial radiosurgery dosimetry end-to-end audit. <i>British Journal of Radiology</i> , 2017, 90, 20170053.	1.0	23
34	Challenges in calculation of the gamma index in radiotherapy – Towards good practice. <i>Physica Medica</i> , 2017, 36, 1-11.	0.4	121
35	Radiotherapy reference dose audit in the United Kingdom by the National Physical Laboratory: 20 years of consistency and improvements. <i>Physics and Imaging in Radiation Oncology</i> , 2017, 3, 21-27.	1.2	16
36	Feasibility study of silica bead thermoluminescence detectors (TLDs) in an external radiotherapy dosimetry audit programme. <i>Radiation Physics and Chemistry</i> , 2017, 141, 251-256.	1.4	5

#	ARTICLE	IF	CITATIONS
37	A virtual dosimetry audit – Towards transferability of gamma index analysis between clinical trial QA groups. <i>Radiotherapy and Oncology</i> , 2017, 125, 398-404.	0.3	12
38	1st European Congress of Medical Physics September 1-4, 2016; Medical Physics innovation and vision within Europe and beyond. <i>Physica Medica</i> , 2017, 41, 1-4.	0.4	0
39	A multi-centre analysis of radiotherapy beam output measurement. <i>Physics and Imaging in Radiation Oncology</i> , 2017, 4, 39-43.	1.2	11
40	The use of log file analysis within VMAT audits. <i>British Journal of Radiology</i> , 2016, 89, 20150489.	1.0	19
41	EP-1935: Impact of standardised codes of practice and related audit on radiotherapy dosimetry over 20 years. <i>Radiotherapy and Oncology</i> , 2016, 119, S918.	0.3	0
42	Changes in Patterns of Intensity-modulated Radiotherapy Verification and Quality Assurance in the UK. <i>Clinical Oncology</i> , 2016, 28, e28-e34.	0.6	17
43	The role of complexity metrics in a multi-institutional dosimetry audit of VMAT. <i>British Journal of Radiology</i> , 2016, 89, 20150445.	1.0	34
44	Current status of cranial stereotactic radiosurgery in the UK. <i>British Journal of Radiology</i> , 2016, 89, 20150452.	1.0	22
45	Feasibility of using glass-bead thermoluminescent dosimeters for radiotherapy treatment plan verification. <i>British Journal of Radiology</i> , 2015, 88, 20140804.	1.0	10
46	Expanding the scientific role of medical physics in radiotherapy: Time to act. <i>Radiotherapy and Oncology</i> , 2015, 117, 401-402.	0.3	15
47	Evaluation of Gafchromic EBT-XD film, with comparison to EBT3 film, and application in high dose radiotherapy verification. <i>Physics in Medicine and Biology</i> , 2015, 60, 8741-8752.	1.6	81
48	Radiotherapy dosimetry audit: three decades of improving standards and accuracy in UK clinical practice and trials. <i>British Journal of Radiology</i> , 2015, 88, 20150251.	1.0	50
49	A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: the application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes. <i>British Journal of Cancer</i> , 2015, 112, 32-38.	2.9	29
50	Inter-departmental dosimetry audits – development of methods and lessons learned. <i>Journal of Medical Physics</i> , 2015, 40, 183.	0.1	10
51	Global Harmonization of Quality Assurance Naming Conventions in Radiation Therapy Clinical Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1242-1249.	0.4	44
52	A multi-institutional dosimetry audit of rotational intensity-modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 113, 272-278.	0.3	49
53	Glass beads and Ge-doped optical fibres as thermoluminescence dosimeters for small field photon dosimetry. <i>Physics in Medicine and Biology</i> , 2014, 59, 6875-6889.	1.6	19
54	Radiation therapy quality assurance in clinical trials – Global harmonisation group. <i>Radiotherapy and Oncology</i> , 2014, 111, 327-329.	0.3	55

#	ARTICLE	IF	CITATIONS
55	Energy response of glass bead TLDs irradiated with radiation therapy beams. <i>Radiation Physics and Chemistry</i> , 2014, 104, 208-211.	1.4	18
56	Low-cost commercial glass beads as dosimeters in radiotherapy. <i>Radiation Physics and Chemistry</i> , 2014, 97, 95-101.	1.4	48
57	Final long-term results of a phase I/II study of dose-escalated intensity-modulated radiotherapy for locally advanced laryngo-hypopharyngeal cancers. <i>Oral Oncology</i> , 2014, 50, 1089-1097.	0.8	21
58	Preliminary investigations of two types of silica-based dosimeter for small-field radiotherapy. <i>Radiation Physics and Chemistry</i> , 2014, 104, 139-144.	1.4	3
59	Dose-response analysis of parotid gland function: What is the best measure of xerostomia?. <i>Radiotherapy and Oncology</i> , 2013, 106, 341-345.	0.3	24
60	A comparison of the gamma index analysis in various commercial IMRT/VMAT QA systems. <i>Radiotherapy and Oncology</i> , 2013, 109, 370-376.	0.3	130
61	Volumetric-modulated arc therapy (RapidArc) vs. conventional fixed-field intensity-modulated radiotherapy for 18F-FDG-PET-guided dose escalation in oropharyngeal cancer: A planning study. <i>Medical Dosimetry</i> , 2013, 38, 18-24.	0.4	7
62	A methodology for dosimetry audit of rotational radiotherapy using a commercial detector array. <i>Radiotherapy and Oncology</i> , 2013, 108, 78-85.	0.3	34
63	Development of a novel treatment planning test for credentialing rotational intensity-modulated radiotherapy techniques in the UK. <i>British Journal of Radiology</i> , 2013, 86, 20120315.	1.0	12
64	A critical evaluation of the PTW 2DARRAY seven29 and OCTAVIUS II phantom for IMRT and VMAT verification. <i>Journal of Applied Clinical Medical Physics</i> , 2013, 14, 274-292.	0.8	47
65	Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 43-54.	5.1	303
66	Dose-Escalated Intensity-Modulated Radiotherapy Is Feasible and May Improve Locoregional Control and Laryngeal Preservation in Laryngo-Hypopharyngeal Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 539-547.	0.4	40
67	Dosimetric explanations of fatigue in head and neck radiotherapy: An analysis from the PARSPORT Phase III trial. <i>Radiotherapy and Oncology</i> , 2012, 104, 205-212.	0.3	73
68	Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. <i>Lancet Oncology</i> , The, 2011, 12, 127-136.	5.1	1,407
69	Volumetric modulated arc therapy: a review of current literature and clinical use in practice. <i>British Journal of Radiology</i> , 2011, 84, 967-996.	1.0	503
70	Intensity-modulated Radiotherapy Allows Escalation of the Radiation Dose to the Pelvic Lymph Nodes in Patients with Locally Advanced Prostate Cancer: Preliminary Results of a Phase I Dose Escalation Study. <i>Clinical Oncology</i> , 2010, 22, 236-244.	0.6	38
71	Impact of Intrafraction Motion on TCP and Rectal NTCP Values in Patients Receiving IG-IMRT for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, S363-S364.	0.4	2
72	Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer. <i>British Journal of Radiology</i> , 2009, 82, 585-594.	1.0	43

#	ARTICLE	IF	CITATIONS
73	Dosimetry audit for a multi-centre IMRT head and neck trial. <i>Radiotherapy and Oncology</i> , 2009, 93, 102-108.	0.3	52
74	A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2007, 85, 36-41.	0.3	53
75	Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: Acute toxicity results of a phase I study. <i>Radiotherapy and Oncology</i> , 2007, 85, 58-63.	0.3	50
76	Target Volume Definition for Head and Neck Intensity Modulated Radiotherapy: Pre-clinical Evaluation of PARSPORT Trial Guidelines. <i>Clinical Oncology</i> , 2007, 19, 604-613.	0.6	32
77	Intensity Modulated Radiotherapy Improves Target Coverage and Parotid Gland Sparing When Delivering Total Mucosal Irradiation in Patients With Squamous Cell Carcinoma of Head and Neck of Unknown Primary Site. <i>Medical Dosimetry</i> , 2007, 32, 188-195.	0.4	24
78	A quantitative study of IMRT delivery effects in commercial planning systems for the case of oesophagus and prostate tumours. <i>British Journal of Radiology</i> , 2006, 79, 401-408.	1.0	5
79	Intensity Modulated Radiotherapy in Cancer of the Larynx. , 2006, , 335-344.		0
80	Dose to Bone Marrow Using IMRT Techniques in Prostate Cancer Patients. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 172-178.	1.0	33
81	The impact of introducing intensity modulated radiotherapy into routine clinical practice. <i>Radiotherapy and Oncology</i> , 2005, 77, 241-246.	0.3	103
82	Intensity-modulated radiotherapy improves target coverage, spinal cord sparing and allows dose escalation in patients with locally advanced cancer of the larynx. <i>Radiotherapy and Oncology</i> , 2004, 70, 189-198.	0.3	55
83	Verification of patient position and delivery of IMRT by electronic portal imaging. <i>Radiotherapy and Oncology</i> , 2004, 73, 339-347.	0.3	23
84	Implementation of IMRT in the radiotherapy department. <i>British Journal of Radiology</i> , 2003, 76, 850-856.	1.0	24
85	In regard to Lee et al., <i>IJROBP</i> 2002;53:630-637. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 1150.	0.4	1
86	IMRT clinical implementation: Prostate and pelvic node irradiation using Helios and a 120-leaf multileaf collimator. <i>Journal of Applied Clinical Medical Physics</i> , 2002, 3, 273-284.	0.8	27
87	The use of electronic portal imaging to verify patient position during intensity-modulated radiotherapy delivered by the dynamic MLC technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 1225-1234.	0.4	21
88	IMRT clinical implementation: Prostate and pelvic node irradiation using Helios and a 120-leaf multileaf collimator. <i>Journal of Applied Clinical Medical Physics</i> , 2002, 3, 273.	0.8	29